The focus of this review focuses on musculoskeletal effects of testosterone and the 24 place of these benefits in the discussion of risk-benefit ratio for testosterone 25 replacement therapy. 26 27 28
Abstract 29
The value of testosterone replacement therapy (TRT) for older men is currently a topic of 30 intense debate. While US testosterone prescriptions have tripled in the last decade (9), debate 31 continues over the risks and benefits of TRT. TRT is currently prescribed for older men with 32 either low serum testosterone (T) or low T plus accompanying symptoms of hypogonadism. 33
The normal range for serum testosterone is 300 to 1000 ng/dL. Serum T ≤ 300 ng/dL is 34 considered to be low and T ≤ 250 is considered to be frank hypogonadism. Most experts 35 support TRT for older men with frank hypogonadism and symptoms. Treatment for men who 36 simply have low T remains somewhat controversial. TRT is most frequently administered by 37 i.m. injection of long-acting T esters or transdermally via patch or gel preparations and 38 infrequently via oral administration (see Table 1 ). TRT produces a number of established 39 benefits in hypogonadal men, including increased muscle mass and strength, decreased fat 40 mass, increased bone mineral density and improved sexual function and in some cases those 41 benefits are dose-dependent. For example, doses of TRT administered by i.m. injection are 42 typically higher than those administered transdermally, which results in greater musculoskeletal 43 benefits. TRT also produces known risks including development of polycythemia (hematocrit > 44 50) in 6% of those treated, decrease in HDL, breast tenderness and enlargement, prostate 45 enlargement, increases in serum PSA and prostate-related events and may cause suppression 46 of the hypothalamic-pituitary-gonadal axis. Importantly, TRT does not increase the risk of 47 prostate cancer. Putative risks include edema and worsening of sleep apnea. Several recent 48 reports have also indicated that TRT may produce cardiovascular (CV) risks, while others report 49 no risk or even benefit. To address the potential CV risks of TRT, we have recently reported via 50 meta-analysis that oral TRT increases CV risk and suggested that the CV risk profile for i.m. 51
TRT may be better than that for oral or transdermal TRT. 52
Scope of the review. Herein, we review the literature which indicates that i.m. injected TRT 53 produces greater musculoskeletal benefits and lower cardiovascular risk compared to 54 transdermal TRT. TRT also produces risk of polycythemia, prostate enlargement and 55 suppression of the hypothalamic-pituitary-gonadal axis. The effects of injection vs. transdermal 56 administration on these risks are unknown. We also review the literature discussing the use of 57 5α-reductase inhibitors as a promising means of improving the safety profile of TRT. 58 serum T should be based on the average of 2 blood samples drawn before 10:00 AM. Kaufman 66 and Vermeulen (45) have reviewed the literature and reported that approximately 20% of men 67 over the age of 60 have a serum total T concentration of ≤ 320 ng/dL. Similarly, we have 68 reported (19) that 24% of men over 60 have a serum total T of ≤ 300 ng/dL. Additionally, 69 hypogonadism is sometimes defined as low free T or low bioavailable T (bioT). In this regard, a 70 small fraction of circulating T is unbound while the bulk is either loosely bound to albumin or 71 very tightly bound to steroid hormone binding globulin (SHBG) . BioT is the sum of the free and 72 albumin-bound T and represents the most physiologically important T fraction. BioT is the 73 fraction able to cross cell membranes and bind to androgen receptors (ARs). An increase in 74 SHBG due to aging (85), traumatic events, such as spinal cord injury (11) will result in reduced 75 bioT. Total T assays are available to most clinicians, while free T and bioT assays are less 76 available. However, serum bioT may be estimated from serum total T, SHBG and albumin 77 using one of several empiric formulas (57, 86). The Endocrine Society recommends that 78 treatment be individualized including a determination of whether the patient has primary 79 hypogonadism (primary deficit lies within the testes) or secondary hypogonadism (primary 80 deficit lies outside of the testes) (13). When T-enanthate or T-cypionate are injected, one 81 should aim for a serum total T concentration of 400 -700 ng/dL at one week after the most 82 recent injection. 83
Modes of TRT and doses delivered 84
Testosterone use in the United States increased more than 3-fold between 2000 and 2011 85 (36) . The most common modes of T administration are patch and gel preparations and i.m. 86 injection of long acting T esters. Transdermal doses are typically intended to be replacement 87 doses with the patch being administered at a doses of 5-10 mg T/day and gel administration 88 involving a somewhat greater amount of T due to low absorption (see Table 1 ). Injection of T-89 esters typically delivers higher amounts, 50 to 400 mg every two to 4 weeks. Esters such as T-90 enanthate or T-cypionate have virtually no aqueous solubility and remain in the muscle depot 91 until muscle esterase activity releases T, which can then enter the circulation. Administered T 92 may be converted to estradiol via the action of aromatase or to dihydrotestosterone (DHT) by 93 the action of 5-α reductase (see Figure 1) , both of which exert biologic actions at estrogen 94 receptor and ARs, respectively. As such, T may be considered both a hormone (because it 95 binds to ARs) and a prohormone for the synthesis of estradiol and DHT. Interestingly, the mode 96
of TRT administration appears to alter the metabolism of T, as evidenced by our recent meta-97 analysis (18) reporting that transdermal T (patch and gel) elevated serum DHT 5.46 fold, while 98 i.m. injected T elevates serum DHT only 2.2 fold. This surprising phenomenon occurs despite 99 the fact that transdermal and i.m. TRT elevated serum T to a roughly similar degree and may be 100 explained by relatively high expression of 5-α reductase in skin (40) vs. lower expression in 101 skeletal muscle (93) . 102
Effect of TRT on muscle, bone and body composition 103
Age is accompanied by a progressive decline in muscle mass with a decrease in both the 104 number and diameter of muscle fibers, especially type II (fast) fibers (59). Fiber loss with aging 105 is secondary to a loss in motor neurons (81). TRT increases muscle mass and strength by 106 increasing the cross-sectional area of both type I and type II fibers in a dose-dependent manner 107 (70). At low replacement doses, T administration produces muscle protein accretion mainly by 108 preventing protein degradation (30), which is mediated, at least in part, by an increase 109 phosphorylation-induced inactivation of FOXO3a (89). At higher doses, T also stimulates 110 TRT were much less. We surveyed 10, mostly more recent, RCTs of TRT in older men lasting 126 12 weeks or more and reporting 1-RM strength as an outcome. None of the four transdermal 127 studies (10, 37, 47, 58) reported a significant increase in 1-RM strength. In contrast, all six of 128 the i.m. injection studies (19, 22, 30, 64, 75, 78) reported significantly increased strength. We 129 administered a moderately high dose of 125 mg/week T-enanthate i.m. to older hypogonadal 130 men and observed increases of 8-14% in 1-RM strength over a 12-month period, with most of 131 the improvement occurring during the first 3 months (19). Storer et al. (75) administered a 132 higher dose of 300 mg T/week i.m. to young eugonadal men for 5 months and reported that 1-133 RM leg press strength was increased 23% and leg press power by 39%. The benefits with 134 even higher doses of i.m. T (300 to 600 mg/week) are even more substantial (upwards of 20% 135 increase in 1-RM strength in older men over 20 weeks), but the number of adverse events 136 observed at these doses preclude their clinical implementation (14). Thus injected TRT has 137 value for increasing muscle strength in older men, especially because not all patients have the 138 means or ability to exercise. In addition, hypogonadism may reduce both the response to and 139 the motivation for resistance exercise. 140
Effect of TRT on bone 141
Men over the age of 65 are subject to an increased incidence of osteoporosis and to 142 increased falls and fractures ultimately contributing to increased mortality (15). In older men, 143 low serum T is associated with osteopenia (49) and increased fracture risk (55). T 144 administration increases BMD, mainly by suppressing bone resorption (12, 16) . TRT may 145 increase BMD in men by a direct AR-mediated effect of T or by an indirect action requiring 146 conversion to estradiol (94). In this regard, low serum estradiol is more strongly associated with 147 osteopenia in older men than is low serum T (49). Interestingly, the indirect effects of T may be 148 cessation of the trial. However, it should be noted that the trial was not designed to assess pre-205 specified CV surrogate outcomes or clinical endpoints. Furthermore, the increased CV-related 206 adverse events were considered as a composite endpoint including events of varying severity 207 and mechanisms. Vigen et al. (87) , in a retrospective study of men with low T and angina who 208 also had undergone angiography, reported a higher CV risk in those who subsequently received 209 T than in those who did not. Methodology of this paper was criticized in numerous letters to the 210 editor of JAMA. Another observational study by Finkle et al. (31) reported a greater risk of 211 myocardial infarction in men who had received a prescription for T. Finally, Xu and colleagues 212 (91) published a 2013 meta-analysis of CV adverse events in 27 randomized controlled trials 213 (RCTs) of TRT published through December of 2012 and reported a statistically significant odds 214 ratio (OR) of 1.54, indicating that participants receiving TRT were 54% more likely to develop 215 CV AEs. As a result of these studies, the FDA (4), VA (1) and Endocrine Society (2) have all 216 issued advisories calling for more research on potential TRT-related CV risks. The latest FDA 217 Drug Safety Communication, issued march 2015, will require manufacturers of approved 218 testosterone products to conduct clinical trials assessing risks of heart attack and stroke (3). 219
We have recently performed the largest meta-analysis of RCTs to date (including 35 RCTs 220 of TRT lasting 12 weeks or more, reporting CV adverse events and published through May of 221 2014) evaluating TRT-related CV risks (18) and using guidelines for analysis of low-frequency 222 events (95). Our main finding was that the form of testosterone (18) administration influenced 223 its CV risk profile (see Table 2 ). Specifically, we reported the following new and significant 224 It is well-described that low serum T is associated with poor CV outcomes including 239 coronary artery disease, heart failure and stroke (82). In particular, Shores et al. have reported 240 that low serum T in men is associated with increased incidence of CV disease and increased 241 all-cause mortality (66). In addition, several studies directly demonstrate CV benefits of TRT. 242 The role of DHT in responses to testosterone 254
As previously discussed, 5α-reductase enzyme actively converts T to DHT in a local tissue-255 specific manner, which local increases in action. As such, it remains biologically and clinically 256 important to evaluate the role of 5α-reductase in mediating the effects of TRT, especially given 257 that DHT binds to ARs with approximately three times the affinity of T (93) T-induced increases in lean mass and 1-RM strength. In addition, both our laboratory (19) and 264 others (7) have shown that DHT is not required for the T-induced increase in BMD or hematocrit 265
(62). Macukat et al. have shown that dutasteride administration does not decrease, BMD in 266
older men (51). Taken together, these studies suggest that conversion of T to DHT is not 267 required for the effects of TRT on muscle, bone or hematocrit. In contrast, some evidence 268 suggests that DHT may cause the putative risks resulting from TRT. As discussed above, the 269 higher circulating DHT levels, obtained with transdermal as opposed to injected T, may be 270 responsible for the trend for increased CV risk with transdermal TRT. In observational studies, 271
Shores et al have shown that shown that high DHT is associated with increased cardiovascular 272 events (66) and increased incident ischemic stroke (65). Interestingly, Zwadlo et al. (96) have 273 shown that cardiac expression of 5-α reductase is markedly increased in humans with heart 274 failure and in a mouse aortic-constriction model of heart failure. In the mouse model, treatment 275 with finasteride attenuates cardiac hypertrophy and improves left ventricular function. Similarly, 276
Rubio-Gayosso et al. (63) reported that T-administration protects against cardiac 277
ischemia/reperfusion (I/R) injury in male rats, and that inhibition of 5α-reductase reduces I/R 278 injury in both orchiectomized and intact rats, while DHT administration worsens I/R damage. 279
Taken together, this evidence suggests that conversion of T to DHT may underlie CV AEs 280 resulting from TRT. 281
Combination therapy of T plus a 5-α reductase inhibitor 282
The observation that DHT may mediate several AEs resulting from TRT but is not required 283 for musculoskeletal benefits, results in the proposed addition of finasteride or dutasteride to 284 improve the safety of TRT. In our study of 1 year of i.m. TRT in older men, T alone caused a 285 40% increase in prostate volume, while T + finasteride produced the same musculoskeletal 286 benefits as T alone, but with no prostate enlargement (19). Similarly, Amory et al. (7) reported 287 that T + finasteride produced less prostate enlargement than did T alone, and did not inhibit T-288 induced increases in BMD, although T-induced increases in muscle strength were not observed 289 in this study. In a trial of 18,882 men, Thompson et al. demonstrated that finasteride reduced 290 the incidence of all prostate cancer by 30%, while increasing the incidence of high-grade 291 prostate cancer by 17% (81). However, this study may have underestimated the benefit of 292 finasteride because finasteride shrinks the prostate, making detection of prostate cancer easier. 293
Taken together, these findings indicate that co-administration of finasteride with T may increase 294 its safety without sacrificing benefits. 295
Summary and recommendations 296
For treatment of older hypogonadal men, there are advantages to administering TRT by 297 injection, rather than transdermally or orally. First, the musculoskeletal benefits are greater, due 298 to the higher doses administered i.m. vs transdermally. Second, although the doses are higher, 299 i.m. TRT may not pose the same CV risks that result from transdermal TRT. A possible 300 explanation for the latter phenomenon is that transdermal T causes greater elevation of serum 301 DHT, due to significant expression of 5α-reductase in skin, but not in muscle. Meta-analysis of 302 existing randomized placebo-controlled trial is, to date, insufficient to definitively assess the CV 303 effects of TRT. However, existing data exhibit trends indicting 1) that TRT may not accelerate 304 underlying early-stage prostate cancer 2) that transdermal TRT may cause CV risk and 3) that 305 i.m. injected TRT may cause CV benefit. In addition, several studies demonstrate that in older 306 hypogonadal men, the combination of i.m. T plus finasteride produces musculoskeletal benefits 307 without the prostate enlargement that results from T alone (7, 19) . Finasteride produces 308 relatively few adverse events and may also produce cardiovascular benefits and/or reduce 309 prostate cancer by reducing DHT. While further research is needed, it appears at this time that 310 i.m. injected T plus finasteride may be both the safest and most effective treatment for older 311 hypogonadal men. 
